Rumsfeld Swine Flu Connection!


The Rumsfeld Swine Flu connection!

Swine Flu Vaccination Propaganda from 1976…

Check out this Rumsfeld connection:

“The Rumsfeld history starts in 1976, when a military recruit in New Jersey died from a flu that experts speculated might be the “swine flu” virus of 1918 pandemic fame. As Sargent tells it, Rumsfeld, who was then and is again the nation’s secretary of defense, made the imminent “swine flu” a political issue to add some spark to the campaign of President Ford, an interim leader without a cause. At Rumsfeld’s urging, the administration would ensure that “every man, woman and child” was vaccinated. Huge amounts of vaccine were produced and distributed quickly.”– Lisa Parsons……

who gains from sales of Tamiflu


7 responses to “Rumsfeld Swine Flu Connection!

  1. The Rumsfeld Swine Flu connection!
    Posted April 26th, 2009 by Ron Paul is Tru…
    Swine Flu Vaccination Propaganda from 1976

    Check out this Rumsfeld connection

    The Rumsfeld Swine Flu connection!
    Posted April 26th, 2009 by Ron Paul is Tru…
    Swine Flu Vaccination Propaganda from 1976

    Check out this Rumsfeld connection:

    “The Rumsfeld history starts in 1976, when a military recruit in New Jersey died from a flu that experts speculated might be the “swine flu” virus of 1918 pandemic fame. As Sargent tells it, Rumsfeld, who was then and is again the nation’s secretary of defense, made the imminent “swine flu” a political issue to add some spark to the campaign of President Ford, an interim leader without a cause. At Rumsfeld’s urging, the administration would ensure that “every man, woman and child” was vaccinated. Huge amounts of vaccine were produced and distributed quickly.”– Lisa Parsons

    Who Owns the rights on Tamiflu

    by Joseph Mercola

    Finally, the pieces of the puzzle start to add up. Not long ago, President Bush sought to instill panic in this country by telling us a minimum of 200,000 people will die from the avian flu pandemic, but it could be as bad as 2 million deaths in this country alone.

    This hoax is then used to justify the immediate purchase of 80 million doses of Tamiflu, a worthless drug that in no way shape or form treats the avian flu, but only decreases the amount of days one is sick and can actually contribute to the virus having more lethal mutations.

    So the U.S. placed an order for 20 million doses of this worthless drug at a price of $100 per dose. That comes to a staggering $2 billion.

    We are being told that Roche manufactures Tamiflu and, in a recent New York Times article, they were battling whether or not they would allow generic drug companies to help increase their production.

    But if you dig further you will find that a drug was actually developed by a company called Gilead that 10 years ago gave Roche the exclusive rights to market and sell Tamiflu.

    Ahh, The Plot Thickens…

    If you read the link below from Gilead, you’ll discover Defense Secretary Donald Rumsfeld was made the chairman of Gilead in 1997.

    Since Rumsfeld holds major portions of stock in Gilead, he will handsomely profit from the scare tactics of the government that is being used to justify the purchase of $2 billion of Tamiflu.



    Donald H. Rumsfeld Named Chairman of Gilead Sciences

    Foster City, CA, January 3, 1997 – Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Dr. Riordan will continue to serve as a director on the board.

    “Gilead is fortunate to have had Don Rumsfeld as a stalwart board member since the company’s earliest days, and we are very pleased that he has accepted the Chairmanship,” Dr. Riordan said. “He has played an important role in helping to build and steer the company. His broad experience in leadership positions in both industry and government will serve us well as Gilead continues to build its commercial presence.”

    “In my years with Gilead, I have witnessed the evolution of one of the industry’s premier biotechnology companies,” Mr. Rumsfeld said. “Michael Riordan’s founding vision and enormous accomplishments are evident in the VISTIDE® product approval, deep pipeline and talented team that will continue to move Gilead to develop novel treatments for viral diseases.”

    Mr. Rumsfeld, who joined Gilead as a director in 1988, is currently in private business and is distinguished for his accomplishments in both industry and government. Mr. Rumsfeld served as chief executive officer of G.D. Searle, a worldwide pharmaceutical company, from 1977 to 1985. During this time, his stewardship of Searle earned him awards as the Outstanding Chief Executive Officer in the pharmaceutical industry in 1980 and 1981. He also served as chairman and chief executive of General Instrument Corporation, a diversified electronics company and world leader in broadband and all digital high definition television technology.

    A graduate of Princeton University, Mr. Rumsfeld has served in numerous positions of public service, including four terms in the U.S. Congress, U.S. Ambassador to NATO, White House Chief of Staff and as the 13th Secretary of Defense. In 1977, Mr. Rumsfeld was awarded the nation’s highest civilian award, the Presidential Medal of Freedom.

    In addition to Gilead, Mr. Rumsfeld presently serves as an advisor to several companies and as a member of the board of directors of ABB AB; Gulfstream Aerospace Corp.; Kellogg; Metricom, Inc.; Sears, Roebuck and Co. and Tribune Company. Mr. Rumsfeld’s current civic activities include service on the board of trustees of the Eisenhower Exchange Fellowship, Freedom House and the RAND Corporation.

    Dr. Riordan will continue to assist the company with strategic direction through his involvement on the board of directors. Since founding the company in 1987, Riordan has overseen Gilead’s evolution to a leading biotechnology company with its first approved product and a diversified pipeline of antiviral therapies.

    “Michael Riordan’s vision and leadership have guided Gilead from a start-up to a commercial company, and we are pleased to rely on his continued counsel as an active board member,” John C. Martin, Ph.D., President and Chief Executive Officer of Gilead said. “Over the past several years, I have enjoyed working with Don Rumsfeld as an active director and look forward to his new role as Chairman as we continue to build the Gilead business.”

    Gilead Sciences is a leader in the discovery and development of a new class of human therapeutics based on nucleotides, the building blocks of DNA and RNA. In 1996, Gilead’s first product, VISTIDE (cidofovir injection), was cleared by the U.S. Food & Drug Administration for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Gilead has other nucleotide product candidates in human testing for the potential treatment of viral diseases caused by CMV, human immunodeficiency virus (HIV), hepatitis B virus, herpes simplex virus and human papillomavirus.

    The Company’s research and development efforts encompass three interrelated programs: small molecule antivirals, cardiovascular therapeutics and genetic code blockers for cancer and other diseases. Gilead’s expertise in each of these areas has also resulted in the discovery and development of non-nucleotide product candidates, including neuraminidase inhibitors for the potential treatment and prevention of viral influenza and protease inhibitors for the potential treatment of HIV

    copyright Gilead Sciences Inc.

    link to original press prelease Gilead Sciences Inc


    Biotech firm wants to regain control of avian flu drug
    Gilead says deal with Roche Inc. threatens Tamiflu’s production

    Sabin Russell, Chronicle Medical Writer

    Friday, June 24, 2005

    Citing “ongoing neglect of the product,” a Bay Area biotech company is attempting to reclaim control of Tamiflu, an antiviral drug it sold to Swiss pharmaceutical giant Roche Inc. that has since emerged as the world’s only practical weapon against a potential pandemic of avian flu.

    The Foster City-based Gilead Sciences, best known for its AIDS drug Viread, notified Roche on Thursday that it was terminating the 1996 agreement that gave the Swiss company exclusive rights to make and sell Tamiflu.

    Gilead executives disclosed that they have been peppering Roche with complaints about its marketing of Tamiflu for five years, and that manufacturing glitches have been responsible for earlier shortages of a drug now deemed vitally important to public health.

    Formerly a lackluster seller in the market for drugs to treat influenza, Tamiflu has become a valuable commodity since December 2003, when scientists became alarmed that a new flu strain that primarily killed chickens in Southeast Asia was starting to kill people who lived in close proximity to the birds.

    In April, Roche reported its first quarter sales of Tamiflu quadrupled to $330 million.

    Copyright San Francisco Chronicle 2005



    Michel Chossudovsky is a frequent contributor to Global Research. Global Research Articles by Michel Chossudovsky



    Rumsfeld’s growing stake in Tamiflu
    Defense Secretary, ex-chairman of flu treatment rights holder, sees portfolio value growing.
    October 31, 2005: 10:55 AM EST
    By Nelson D. Schwartz, Fortune senior writer

    NEW YORK (Fortune) – The prospect of a bird flu outbreak may be panicking people around the globe, but it’s proving to be very good news for Defense Secretary Donald Rumsfeld and other politically connected investors in Gilead Sciences, the California biotech company that owns the rights to Tamiflu, the influenza remedy that’s now the most-sought after drug in the world.

    Rumsfeld served as Gilead (Research)’s chairman from 1997 until he joined the Bush administration in 2001, and he still holds a Gilead stake valued at between $5 million and $25 million, according to federal financial disclosures filed by Rumsfeld.

    on Aspartame and how the FDA fought it for almost 16 years, Rumsfeld headed the company to push it.. That motherf&#$er has been in the business of intentionally harming people for a long time.




  3. Serious Vaccine Reactions Deemed Mere ‘Coincidence’
    October 20, 2009 · 2 Comments
    Serious Vaccine Reactions to Now Be Called ‘Coincidence’? | Oct 20 2009

    by Dr. Mercola

    Every day Americans wake up to news reports that warn us about the dangers of influenza, especially the new H1N1 “swine flu”.

    But swine flu is mild for most people and the virus is not mutating into a more serious form.

    Millions of people around the world have recovered from swine flu, and millions more will get sick with fevers, body aches, nasal congestion, cough and sometimes diarrhea and vomiting and recover from it this year and next year without any complications.

    Nonetheless, wide-scale vaccination is being encouraged — even though swine flu vaccines have been tested on only a few thousand healthy Americans for a few weeks. There is little or no information about how safe the vaccine is for pregnant women and chronically ill or disabled children.

    If you or your child are injured from getting a flu swine flu shot, you are on your own. Congress has shielded the vaccine manufacturers and any person giving swine flu shots from lawsuits if people get hurt.

    There is no funded government vaccine injury compensation program for swine flu vaccine.

    Do NOT let a doctor or anyone else tell you that a serious health problem you or your child experiences after vaccination is a coincidence and allow more shots to be given until you know for sure.

    The most tragic cases of vaccine injury occur when vaccine reaction symptoms are dismissed as a ‘coincidence” and more vaccines are given that result in more severe symptoms — and sometimes end with permanent brain and immune system damage or death.

    But while Americans are still debating whether to roll up their sleeves for a swine flu shot, companies have already figured it out: vaccines are good for business.

    Drug companies have sold $1.5 billion worth of swine flu shots, in addition to the $1 billion for seasonal flu they booked earlier this year. These inoculations are part of a much wider and rapidly growing $20 billion global vaccine market.

    “The vaccine market is booming,” says Bruce Carlson, spokesperson at market research firm Kalorama, which publishes an annual survey of the vaccine industry. “It’s an enormous growth area for pharmaceuticals at a time when other areas are not doing so well,” he says, noting that the pipeline for more traditional blockbuster drugs such as Lipitor and Nexium has thinned.

    As always with pandemic flus, taxpayers are footing the $1.5 billion check for the 250 million swine flu vaccines that the government has ordered so far and will be distributing free to doctors, pharmacies and schools. In addition, Congress has set aside more than $10 billion this year to research flu viruses, monitor H1N1’s progress and educate the public about prevention.

    Drugmakers pocket most of the revenues from flu sales, with Sanofi-Pasteur, Glaxo Smith Kline and Novartis cornering most of the market.

    But some say it’s not just drugmakers who stand to benefit. Doctors collect copayments for special office visits to inject shots, and there have been assertions that these doctors actually profit handsomely from these vaccinations.

    Full Story

  4. -Swine flu..Anders an health professional!

  5. link above euro-med

    In Germany a scandal is unfolding: The Government and here (German) has for itself and the employees of the ministerial departments ordered Baxter´s Cevalpan without squalene and thimerosal. This “luxury” vaccine is also to be given to the doctors at the Paul Ehrlich Institute, who have been running a propaganda campaign for GSK´s Pandemrix with squalene and thimerosal, which is to be given to the broad German population!!! Also the Federal Defence has ordered the “luxury” vaccine without squalene and thimerosal!!!

    ECDC: 50277 verified A(H1N1)v cases since april im the EU – 77 deaths. During week 42/2009, eight countries reported 3211 newly diagnosed probable* and confirmed cases of influenza A(H1N1)v . Four deaths were reported by Hungary and two by Norway. * See the following.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s